D&MD's Novel Targets in Drug Discovery report provides an overview of the
concept of drug targets, and discusses their place in modern drug discovery.
The report looks at the role of technologies such as genomics, proteomics and
bioinformatics in target identification, as well as describing the downstream
processes such as target validation, lead discovery, lead optimization and
clinical development. It also discusses the various types of drug targets
using specific examples where appropriate and provides an overview of novel
targets currently moving through advanced clinical trials
Table of Contents
EXECUTIVE SUMMARY
CHAPTER 1: HISTORICAL PERSPECTIVE
CHAPTER 2: DRUG DISCOVERY IN THE LATE TWENTIETH CENTURY
The Basis of Inheritance
The Genetic Code
Biotechnology
The Human Genome Project
Celera Enters the Race
The Major Findings
Implications for Drug Discovery
Functional Genomics
Knockouts
Antisense
RNA Interference
Transgenics
Limitations of Gene-modified Animal Models
DNA Microarrays
Target Identification
Target Validation
Lead Discovery
Lead Optimization
Proteomics
Preclinical Development
Clinical Development
CHAPTER 3: DRUG DISCOVERY IN THE POST-GENOMIC ERA
'Traditional' Drug Discovery
The Promise of Genomics
Genomics and Drug Discovery
Unresolved Issues
Reductionism Criticized
Target Identification
Discovery Screens
How Many Targets?
The Druggable Genome
Implications for Drug Discovery
The Importance of Druggability
Predicting Druggability
Artificial Intelligence
CHAPTER 4: THE NATURE OF DRUG TARGETS
Nuclear Receptors
Estrogen Receptors
Retinoid Receptors
Vitamin D Receptors
Glucocorticoid Receptors
Thyroid Hormone Receptors
Peroxisome Proliferator-activated Receptors
Liver X Receptors
Enzymes
Enzyme Inhibitors
Ion channels
Receptors
G proteins
Tyrosine Kinase Receptors
Hormones and Factors
Recent Novel Drug Targets
CHAPTER 5: CONCLUSIONS
CHAPTER 6: COMPANY PROFILES
Aerovance
Alliance Pharmaceutical
Cara Therapeutics
deCODE Genetics
Elbion
Genfit
Nutra Pharma
Prestwick Pharmaceuticals
Solbec Pharmaceuticals
Somaxon
APPENDIX 1: DRUGGABILITY STUDIES
Other Approaches
APPENDIX 2: RECEPTOR FAMILIES
Receptor Families
Muscarinic Acetylcholine Receptors
Adenosine Receptors
Adrenergic Receptors
Angiotensin Receptors
Cannabinoid Receptors
Chemokine Receptors
Cholecystokinin Receptors
Dopamine Receptors
Endothelin Receptors
γ-aminobutyric Acid (GABA) Receptors
Metabotropic Glutamate Receptors
Glucagon Receptors
Histamine Receptors
5-hydroxytryptamine Receptors
Leukotriene Receptors
Melanocortin Receptors
Melatonin Receptors
Neuropeptide Y Receptors
P2Y Receptors
Opioid Receptors
Prostanoid Receptors
Somatostatin Receptors
Urotensin Receptors
VIP and PACAP Receptors
APPENDIX 3: REFERENCES
TABLE OF EXHIBITS
Exhibit 1.1 Traditional Routes of New Drug Discovery
Exhibit 1.2 Examples of Ligands Using Various Second Messenger Systems
Exhibit 1.3 cAMP as a Second Messenger
Exhibit 2.1 Composition of Nucleic Acids
Exhibit 2.2 Gene Expression
Exhibit 2.3 The Central Dogma of Biology
Exhibit 2.4 What Sequencing the Human Genome Does Not Reveal
Exhibit 2.5 The Drug Discovery Process
Exhibit 3.1 Blockbusters whose Success was not Anticipated at the Time of
Selection
Exhibit 3.2 The Biochemical Classes of Therapeutic Drug Targets
Exhibit 3.3 Number of Potential Drug Targets
Exhibit 4.1 Typical Concentrations of Ions Inside and Outside the Cell
Exhibit 4.2 Hormones and Factors used as Drug Targets
Exhibit 4.3 Distribution of Novel Drug Targets (2004 - 2006)
Exhibit 4.4 Novel Targets under Development (January 2004 to November 2006)
Exhibit 4.5 High Potential Drug Development Projects
Exhibit 4.6 High Potential Development Projects involving Novel Targets
Exhibit 4.7 Target Involvement of High Potential Projects
Exhibit 4.8 Large Company Target Involvement
Exhibit 5.1 Total Market Size Distribution
Exhibit App2.1 Pharmaceutical Research Involving Dopamine Receptors
Exhibit App2.2 Classification of 5-HT Receptors
※この商品は英文にてご提供いたします。
【 英文市場調査報告書 】
創薬における新たな標的
Novel Targets in Drug Discovery
出版日 : 2006/11